Clozapine in severe borderline personality disorder

  title={Clozapine in severe borderline personality disorder},
  author={Mark Swinton},
  journal={The Journal of Forensic Psychiatry},
  pages={580 - 591}
  • M. Swinton
  • Published 1 January 2001
  • Psychology, Medicine
  • The Journal of Forensic Psychiatry
A mirror study design monitored the progress of five patients with a diagnosis of borderline personality disorder in a maximum-security hospital who were treated with clozapine. Patients showed a marked reduction in their requirement for nursing observations. This study adds to the evidence that clozapine may be an effective treatment for patients with this disorder. 

Borderline personality disorder and clozapine

Treatment with clozapine resulted in a marked clinical improvement in this patient, a 36 year old female with severe borderline personality disorder with symptoms of psychosis, aggression and violence.

Treatment of severe borderline personality disorder with clozapine

  • A. Vohra
  • Psychology
    Indian journal of psychiatry
  • 2010
The case presented here describes the effectiveness of clozapine in a young female patient with severe BPD (without psychotic features), who had repeated and prolonged periods of hospitalization and was successfully treated with a moderate dose of clazapine, following a failure to improve with other psychotropic medications.

Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital

Clozapine is of benefit in reducing the clinical severity of ASPD and high psychopathy, and improved all symptom domains, especially impulsive-behavioral dyscontrol and anger, and reduced levels of aggression and violence, especially at lower doses.

Clozapine for self-injurious behavior in individuals with borderline personality disorder

Clozapine appears to be efficacious in the management of chronic suicidality, self-injurious behaviors and aggression in patients with severe BPD.

The novel use of clozapine in an adolescent with borderline personality disorder

  • S. ArgentS. Hill
  • Psychology, Medicine
    Therapeutic advances in psychopharmacology
  • 2014
This very preliminary data does nonetheless suggest that clozapine may have a role in treating adolescents with emerging borderline personality disorder when other treatment options have been exhausted.

Clozapine use in women with borderline personality disorder and co‐morbid learning disability

It is found that Clozapine reduces rates of self injury and the use of restraint in a medium secure setting in female patients who have a diagnosis of borderline personality disorder (BPD) and mild learning disability.

Medication for borderline personality disorder: A survey at a secure hospital

  • C. HawJ. Stubbs
  • Psychology, Medicine
    International journal of psychiatry in clinical practice
  • 2011
Clozapine was the most commonly prescribed drug and according to the treating psychiatrists the one most likely to lead to a major improvement in target symptoms, and other psychotropics were generally rated as resulting in minor improvement or no change.

Mood Stabilizers and Novel Antipsychotics in the Treatment of Borderline Personality Disorder

This article focuses on data concerning the efficacy of mood stabilizers in the treatment of BPD.

Clozapine in borderline personality disorder: a review of the evidence.

  • A. BeriJ. Boydell
  • Psychology, Medicine
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists
  • 2014
It is suggested that clozapine may be a beneficial treatment option for BPD especially in controlling symptom severity, psychotic symptoms, impulsivity, self-mutilation, number of days on enhanced observation, use of restraint, and overall functioning.

Effect of clozapine on rates of risk incidents and functioning in female adolescents with a diagnosis of severe emerging emotionally unstable personality disorder

This is the first case series describing the prescription ofClozapine in adolescents with emerging severe emotionally unstable personality disorder, and despite limitations in the study design it provides some evidence for the use of clozapines in this specific patient group.



Psychopharmacology of borderline personality disorder.

  • P. Soloff
  • Psychology
    The Psychiatric clinics of North America
  • 2000

Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder.

The preliminary but nonetheless favorable results suggest that clozapine deserves careful consideration for a controlled study in patients with borderline personality disorder and psychoses, especially if the clinical issues include severe self-mutilation, aggression, and violence.

Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder.

Low-dose clozapine for acute and continuation treatment led to improvement in overall symptomatology in a small sample of severe BPD patients, coupled with an overall improvement.

Pseudoneurotic forms of schizophrenia

It can be demonstrated in follow-up studies that a considerable number of patients with a clinical symptomatology very similar to that seen in schizophrenic patients have short psychotic episodes or later become frankly schizophrenic.

Effect of clozapine on physical and verbal aggression

Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo.

Thiothixene seems to have more than an antipsychotic effect, and a subdiagnosis defined by those symptoms that are drug-responsive, some of which are not included in current diagnostic criteria is suggested.

Lithium carbonate in emotionally unstable character disorder.

It is interpreted that EUCD is closely related to affective illness and that lithium carbonate joins chlorpromazine as a valuable, and perhaps a superior, therapy for EUCD.

Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo.

Haloperidol was superior to both amitriptyline and placebo on a composite measure of overall symptom severity, and was more apparent in self-rated than observer-rated measures.